ViroPharma halts drug trial due to Halozyme delivery tech

Halozyme's ($HALO) drug delivery technology suffered a major setback when drugmaker ViroPharma ($VPHM) ended a Phase II trial that combines Halozyme's rHuPH20 with ViroPharma's drug Cinryze. The subcutaneous immunodeficiency treatment is designed to prevent swelling and painful attacks for patients with hereditary angioedema, a blood protein deficiency, but trials showed that the delivery tech caused unwanted production of antibodies. ViroPharma halted the trial as a precaution, as there were no adverse clinical effects, but Halozyme shares plummeted in response to the news. FierceBiotech's take

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…